Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration.
暂无分享,去创建一个
[1] Vu,et al. Plasma acylation stimulating protein, adipsin and lipids in non‐obese and obese populations , 1999, European journal of clinical investigation.
[2] R. Eckel,et al. Levels of acylation stimulating protein in obese women before and after moderate weight loss. , 1991, International journal of obesity.
[3] A. Fernandez-cruz,et al. Plasma C3d Levels and Ischemic Heart Disease in Type II Diabetes , 1993, Diabetes Care.
[4] H. Baumann,et al. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. , 1992, Molecular and cellular biology.
[5] W. Ricart,et al. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness , 1999, Diabetologia.
[6] H. Colten,et al. Synthesis of complement components in liver and at extrahepatic sites , 1993 .
[7] M. A. Crook,et al. Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.
[8] R. Pratley,et al. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. , 1999, Obesity research.
[9] P. Puddu,et al. Relationship between serum C3 levels and traditional risk factors for myocardial infarction. , 1998, Acta cardiologica.
[10] B. Spiegelman,et al. Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link , 1994, Diabetes.
[11] G. Hansson,et al. Immunological mechanisms in atherosclerosis , 1995, Journal of internal medicine.
[12] C. Martignani,et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. , 2000, European heart journal.
[13] R. DeFronzo,et al. Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.
[14] S. Coppack,et al. Adipose tissue as an endocrine and paracrine organ , 1998, International Journal of Obesity.
[15] G. Hansson,et al. Immune mechanisms in atherosclerosis. , 1989, Arteriosclerosis.
[16] G. Reaven. Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.
[17] D. Raev,et al. Additive effect of diabetes and systemic hypertension on the immune mechanisms of atherosclerosis. , 1996, International journal of cardiology.
[18] P. Puddu,et al. Association of serum C3 levels with the risk of myocardial infarction. , 1995, The American journal of medicine.
[19] K. Cianflone,et al. Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. , 1997, Journal of lipid research.
[20] A. Dalmasso,et al. Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity , 1997, Clinical and experimental immunology.
[21] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[22] B. Spiegelman,et al. Perspectives in Diabetes Tumor Necrosis Factor a: A Key Component of the Obesity-Diabetes Link , 1994 .
[23] K. Cianflone,et al. Plasma acylation-stimulating protein in coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[24] L. Peltonen,et al. Serum complement and familial combined hyperlipidemia. , 1997, Atherosclerosis.
[25] H. Colten,et al. Complement biosynthesis in vitro by rat hepatoma cell strains. , 1975, Journal of immunology.
[26] K. Cianflone,et al. ASP stimulates glucose transport in cultured human adipocytes , 1997, International Journal of Obesity.
[27] K. Cianflone,et al. Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. , 1999, The American journal of physiology.
[28] K. Cianflone,et al. Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein. , 1990, The Journal of clinical investigation.
[29] K. Cianflone,et al. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. , 1993, Metabolism: clinical and experimental.
[30] K. Cianflone,et al. Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. , 1997, Biochimica et biophysica acta.
[31] S. Kado,et al. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus , 1999, Acta Diabetologica.
[32] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[33] E. Ravussin,et al. Use of dual-energy X-ray absorptiometry in obese individuals. , 1995, The American journal of clinical nutrition.
[34] C. Bogardus,et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.
[35] D. Salamon,et al. Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity. , 1998, Diabetes research and clinical practice.
[36] K. Cianflone,et al. The adipsin-acylation-stimulating protein pathway and microenvironmental metabolic regulation. , 1997, World review of nutrition and dietetics.